Has Rajiv Parikh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $947,751 in general payments to Rajiv Parikh, MD across 801 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rajiv Parikh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rajiv Parikh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rajiv Parikh, MD

Family Medicine · Tempe, AZNPI 1811961774

Payments from drug & device makers

$947,751in general payments, 2019–2025

Across 801 payments — averaging $1183.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$347K
Astrazeneca UK Limited$347K
GSK$127K
Chiesi USA, Inc.$45K
Eli Lilly$42K
Sanofi US Services Inc.$25K
plus $14K from 54 others

$600in research payments, 2019–2025

Across 1 payment — averaging $600.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$600

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	70	$347,484
Astrazeneca UK Limited	2	$347,313
GSK	84	$127,450
Chiesi USA, Inc.	6	$44,677
Eli Lilly	3	$42,030
Sanofi US Services Inc.	5	$25,020
Novo Nordisk	120	$3,647
Boehringer Ingelheim	78	$1,378
Eli Lilly Export S.A. Puerto Rico Branch	3	$1,349
Amgen(2 entities)	70	$964
Lilly USA, LLC	64	$842
AbbVie(2 entities)	45	$662
Abbott	26	$538
Bayer	20	$437
Pfizer	19	$423
Johnson & Johnson	14	$315
Indivior Inc.	11	$200
Takeda Pharmaceuticals U.S.A., Inc.	11	$185
Daiichi Sankyo Inc.	5	$162
Teleflex LLC	2	$161
Novartis	9	$152
Merck	9	$136
Esperion Therapeutics, Inc.	8	$125
Boston Scientific	6	$121
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	6	$119
Teva Pharmaceuticals USA, Inc.	5	$103
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	6	$102
Amarin Pharma, Inc.	7	$101
Kowa Pharmaceuticals America, Inc.	7	$100
Corcept Therapeutics	6	$98
Dexcom, Inc.	4	$93
Astellas Pharma US Inc	4	$86
Sanofi-aventis U.S. LLC	5	$80
Ironwood Pharmaceuticals, Inc	4	$66
Braeburn Inc.	3	$62
Mylan Specialty L.p.	4	$56
Hologic Sales And Service, LLC	2	$52
Scilex Pharmaceuticals Inc.	1	$48
Nestle Healthcare Nutrition Inc.	2	$48
Lucid Diagnostics Inc.	1	$47
Sumitomo Pharma America, Inc.	2	$47
Eisai Inc.	3	$46
Biohaven Pharmaceuticals, Inc.	3	$43
Bardy Diagnostics, Inc.	2	$41
Axsome Therapeutics, Inc.	2	$41
Inspire Medical Systems, Inc.	2	$38
Baxter Healthcare	1	$37
Gilead	2	$37
Idorsia Pharmaceuticals US Inc	2	$30
Intuity Medical Inc	2	$30
Sanofi Pasteur Inc.	2	$28
Arbor Pharmaceuticals, Inc.	2	$28
Alfasigma USA, Inc.	2	$25
Nevro Corp.	1	$22
Electromed, Inc.	1	$19
Shield Therapeutics Inc	1	$18
Emergent Biosolutions Inc.	1	$17
Phathom Pharmaceuticals, Inc.	1	$17
Zealand Pharma US, Inc.	1	$16
Medtronic	1	$16

How this compares

$947,751 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona →

Medicare billing

Part B allowed, 2024

$162,870

Medicare patients

310

Services billed

2,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Tempe

Todd DreitzlerTempe$4.7M
Enrique CifuentesTempe$237K
Danielle ArmasScottsdale$73M
Terry O'ReillyMesa$35.8M
Shawn SearleChandler$27M
Corey AndersonMesa$21.5M
Dena PetersenTucson$14.7M
Gerald ShockeyMesa$12.3M
Brock MerrittPhoenix$8.4M
John McGettiganTucson$8.3M

See the full list for Arizona →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →